Opportunities and challenges for TCR mimic antibodies in cancer therapy

Expert Opinion on Biological Therapy

Volumn 16, Issue 8, 2016, Pages 979-987

  Chang, Aaron Y ^a,b   Gejman, Ron S ^a,b   Brea, Elliott J ^a,b   Oh, Claire Y ^a,b   Mathias, Melissa D ^a   Pankov, Dmitry ^a   Casey, Emily ^a   Dao, Tao ^a   Scheinberg, David A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

cancer testis antigen; Monoclonal antibody; neoantigen; oncofetal antigen; oncogene; phage display; TCR; TCR mimic

Indexed keywords

CANCER TESTIS ANTIGEN; DIFFERENTIATION ANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; CANCER ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR;

AMINO ACID SEQUENCE; CANCER THERAPY; CROSS REACTION; DOWN REGULATION; EPIGENETICS; GENETIC REGULATION; HUMAN; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW; ANIMAL; IMMUNOLOGY; MOLECULAR MIMICRY; NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; EPITOPES; HUMANS; MOLECULAR MIMICRY; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL;

EID: 84979052100     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2016.1176138     Document Type: Review

References (59)

1. M.Bassani-Sternberg, S.Pletscher-Frankild, L.J.Jensen, et al. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics. 2015;14(3):658–673. doi:10.1074/mcp.M114.042812.• Demonstration of current capability and limitations using mass spectrometry to determine MHC-presented peptides.
2. L.M.Draper, M.L.M.Kwong, A.Gros, et al. Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6. Clin Cancer Res. 2015;21(19):4431–4439. doi:10.1158/1078-0432.CCR-14-3341.
3. E.Mizukoshi, Y.Nakamoto, H.Tsuji, et al. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer. 2006;118(5):1194–1204. doi:10.1002/ijc.21468.
4. V.P.Wittman, D.Woodburn, T.Nguyen, et al. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J Immunol. 2006;177(6):4187–4195. doi:10.4049/jimmunol.177.6.4187.
5. K.Polakova, D.Plaksin, D.H.Chung, et al. Antibodies directed against the MHC-I molecule H-2Dd complexed with an antigenic peptide: similarities to a T cell receptor with the same specificity. J Immunol. 2000;165(10):5703–5712. doi:10.4049/jimmunol.165.10.5703.• An early description of the approach for mAb with TCR-like features.
6. A.Lev, G.Denkberg, C.J.Cohen, et al. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic sub. Cancer Res. 2002;62(11):3184–3194.
7. G.Denkberg, C.J.Cohen, A.Lev, et al. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc Natl Acad Sci U S A. 2002;99(14):9421–9426. doi:10.1073/pnas.132285699.
8. R.Dahan, Y.Reiter T-cell-receptor-like antibodies - generation, function and applications. Expert Rev Mol Med. 2012;14:e6. doi:10.1017/erm.2012.2.
9. C.J.Luckey, G.M.King, J.A.Marto, et al. Proteasomes can either generate or destroy MHC Class I epitopes: evidence for nonproteasomal epitope generation in the cytosol. J Immunol. 1998;161:112–121.
10. N.Ataie, J.Xiang, N.Cheng, et al. Structure of a TCR mimic antibody with target predicts pharmacogenetics. J Mol Biol. 2015. doi:10.1016/j.jmb.2015.12.002.
11. G.Stewart-jones, A.Hombach, E.Shenderov, et al. Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci. 2009;106(26):10872–10872. doi:10.1073/pnas.0905399106.• Comparisonof the affinity and peptide contacts between a TCR and TCRm Fab against an epitope of NY-ESO1.
12. S.Gill, C.H.June. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev. 2015;263(1):68–89. doi:10.1111/imr.12243.
13. K.J.Curran, R.J.Brentjens. Chimeric antigen receptor T cells for cancer immunotherapy. J Clin Oncol. 2015;33(15):1703–1706. doi:10.1200/JCO.2014.60.3449.
14. R.J.Brentjens, M.L.Davila, I.Riviere, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38. doi:10.1126/scitranslmed.3005930.
15. L.Starck, K.Popp, H.Pircher, et al. Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell-derived T cells. J Immunol. 2014;192(1):206–213. doi:10.4049/jimmunol.1202591.
16. T.Dao, S.Yan, N.Veomett, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med. 2013;5(176). doi:10.1126/scitranslmed.3005661.• Proof that TCRm can be therapeutically active in animal models.
17. A.Sergeeva, G.Alatrash, H.He, et al. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood. 2011;117(16):4262–4272. doi:10.1182/blood-2010-07-299248.• Demonstration of TCRm-mediated cytotoxicity against a tumor-associated differentiation antigen.
18. K.S.R.Sastry, C.T.Too, K.Kaur, et al. Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody. J Virol. 2011;85(5):1935–1942. doi:10.1128/JVI.01990-10.
19. S.Kim, A.K.Pinto, N.B.Myers, et al. A novel T-cell receptor mimic defines dendritic cells that present an immunodominant West Nile virus epitope in mice. Eur J Immunol. 2014;44(7):1936–1946. doi:10.1002/eji.201444450.
20. P.Correale, K.Walmsley, C.Nieroda, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst. 1997;89(4):293–300.
21. M.Almstedt, N.Blagitko-Dorfs, J.Duque-Afonso, et al. The DNA demethylating agent 5-aza-2ʹ-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res. 2010;34(7):899–905. doi:10.1016/j.leukres.2010.02.004.
22. B.D.Valmori, U.Gileadi, C.Servis, et al. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte – defined peptide derived from the tumor antigen MAGE-3. J Exp Med. 1999;189:6.
23. Y.Michaeli, G.Denkberg, K.Sinik, et al. Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies. J Immunol. 2009;182(10):6328–6341. doi:10.4049/jimmunol.0801898.
24. E.Tran, M.Ahmadzadeh, Y.Lu, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Sci (80-). 2015;350(6266):1387–1390. doi:10.1126/science.aad1253.
25. T.Karasaki, K.Nagayama, M.Kawashima, et al. Identification of individual cancer-specific somatic mutations for neoantigen-based immunotherapy of lung cancer. J Thorac Oncol. 2015; doi:10.1016/j.jtho.2015.11.006.• Identification of recurrent neoantigens in lung cancer as potential tumor-specific targets.
26. D.Ito, C.Visus, T.K.Hoffmann, et al. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck. Int J Cancer. 2007;120(12):2618–2624. doi:10.1002/ijc.22584.
27. A.Cai, D.B.Keskin, D.S.DeLuca, et al. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin Cancer Res. 2012;18(20):5761–5772. doi:10.1158/1078-0432.CCR-12-1182.
28. M.Bocchia, T.Korontsvit, Q.Xu, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 1996;87(9):3587–3592.
29. K.Chang, C.J.Creighton, C.Davis, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45(10):1113–1120. doi:10.1038/ng.2764.
30. R.Dahan, J.A.Gebe, A.Preisinger, et al. Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope. J Autoimmun. 2013;47:83–93. doi:10.1016/j.jaut.2013.08.009.
31. th American Society of Hematologists Annual Meeting. Dec 2015. Orlando, FL
32. D.S.Schrump, M.R.Fischette, D.M.Nguyen, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res. 2006;12(19):5777–5785. doi:10.1158/1078-0432.CCR-06-0669.
33. A.O.Gang, T.M.Frøsig, M.K.Brimnes, et al. 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. Blood Cancer J. 2014;4:e197. doi:10.1038/bcj.2014.14.
34. W.Ma, N.Vigneron, J.Chapiro, et al. A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy. Int J Cancer. 2011;129(10):2427–2434. doi:10.1002/ijc.25911.
35. T.Cabrera, M.Angustias Fernandez, A.Sierra, et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol. 1996;50(2):127–134. doi:10.1016/0198-8859(96)00145-0.
36. M.Campoli, S.Ferrone. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008;27(45):5869–5885. doi:10.1038/onc.2008.273.
37. K.Mimura, K.Shiraishi, A.Mueller, et al. The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol. 2013;191(12):6261–6272. doi:10.4049/jimmunol.1301597.
38. B.P.Pollack, B.Sapkota, T.V.Cartee. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res. 2011;17(13):4400–4413. doi:10.1158/1078-0432.CCR-10-3283.
39. R.M.Srivastava, S.Trivedi, F.Concha-Benavente, et al. STAT1-induced HLA class I upregulation enhances immunogenicity and clinical response to anti-EGFR mAb cetuximab therapy in HNC patients. Cancer Immunol Res. 2015;1–11. doi:10.1158/2326-6066.CIR-15-0053.
40. G.L.Palmisano, M.P.Pistillo, P.Capanni, et al. Investigation of HLA class I downregulation in breast cancer by RT-PCR. Hum Immunol. 2001;62(2):133–139. doi:10.1016/S0198-8859(00)00241-X.
41. C.A.Diebolder, F.J.Beurskens, R.N.de Jong, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343:1260–1263. doi:10.1126/science.1248943.
42. B.Verma, F.A.Neethling, S.Caseltine, et al. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models. J Immunol. 2010;184(4):2156–2165. doi:10.4049/jimmunol.0902414.
43. J.M.Hayes, E.F.Cosgrave, W.B.Struwe, et al. Glycosylation and Fc receptors. Curr Top Microbial Immunol. 2014;382:165–199. doi:10.1007/978-3-319-07911-0_8.
44. L.Dubrovsky, D.Pankov, E.J.Brea, et al. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood. 2014;123(21):3296–3304. doi:10.1182/blood-2014-01-549022.
45. N.Veomett, T.Dao, H.Liu, et al. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clin Cancer Res. 2014;20(15):4036–4046. doi:10.1158/1078-0432.CCR-13-2756.
46. T.Dao, D.Pankov, A.Scott, et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol. 2015;33:1–10. doi:10.1038/nbt.3349.•• TCRm engineered into a bispecific T-cell engager format can induce epitope spreading.
47. S.T.Jung, W.Kelton, T.H.Kang, et al. Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity. ACS Chem Biol. 2013;8(2):368–375.
48. M.N.McCracken, A.C.Cha, I.L.Weissman. Molecular pathways: activating T cells after cancer cell phagocytosis from blockade of CD47 “Don’t eat Me” signals. Clin Cancer Res. 2015;21(16):3597–3601. doi:10.1158/1078-0432.CCR-14-2520.
49. M.P.Chao, A.A.Alizadeh, C.Tang, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699–713. doi:10.1016/j.cell.2010.07.044.
50. D.Nagorsen, P.A.Baeuerle. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011;317(9):1255–1260. doi:10.1016/j.yexcr.2011.03.010.
51. K.J.Curran, H.J.Pegram, R.J.Brentjens. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med. 2012;14(6):405–415. doi:10.1002/jgm.2604.
52. th American Society of Hematologists Annual Meeting. Dec 2014. San Francisco, CA
53. G.Zhang, L.Wang, H.Cui, et al. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci Rep. 2014;4:3571. doi:10.1038/srep03571.•• TCRm can be engineered into CAR T cells to direct cellular immunotherapy against intracellular proteins.
54. R.Oren, M.Hod-Marco, M.Haus-Cohen, et al. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. J Immunol. 2014;193(11):5733–5743. doi:10.4049/jimmunol.1301769.
55. E.Klechevsky, M.Gallegos, G.Denkberg, et al. Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Res. 2008;68(15):6360–6367. doi:10.1158/0008-5472.CAN-08-0928.
56. M.R.McDevitt, D.Ma, L.T.L.Lai, et al. Tumor therapy with targeted atomic nanogenerators. Sci (80-). 2001;294(5546):1537–1540. doi:10.1126/science.1064126.
57. K.-W.Tang, B.Alaei-Mahabadi, T.Samuelsson, et al. The landscape of viral expression and host gene fusion and adaptation in human cancer. Nat Commun. 2013;4:2513. doi:10.1038/ncomms3513.
58. O.Makler, K.Oved, N.Netzer, et al. Direct visualization of the dynamics of antigen presentation in human cells infected with cytomegalovirus revealed by antibodies mimicking TCR specificity. Eur J Immunol. 2010;40(6):1552–1565. doi:10.1002/eji.200939875.
59. B.S.Worley, L.T.van den Broeke, T.J.Goletz, et al. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 2001;61(18):6868–6875.